MALVERN, Pa., Sept. 22, 2020 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, will present clinical data and host virtual educational sessions as part of the Clinical TMS Society’s virtual programming.
The Clinical TMS Society, a professional association that aims to optimize awareness and accessibility of transcranial magnetic stimulation (TMS) therapy, is hosting virtual events this year in place of its traditional Annual Meeting, giving attendees a chance to experience educational sessions remotely. As a sponsor, Neuronetics will present a product theater webinar and two virtual poster presentations detailing the company’s latest research with NeuroStar Advanced Therapy in bipolar and unipolar depression.
On Tuesday, September 29 at 5:30 p.m. PDT (8:30 p.m. EDT), Neuronetics will host a product theater webinar that will address these two topics:
Treatment of Bipolar Depression: A Pilot Study—Clinical experience has suggested that NeuroStar Advanced Therapy might be effective for bipolar depression. This presentation will review the existing literature on the efficacy of TMS for bipolar depression and present the findings from a two-center open-label prospective trial of NeuroStar Advanced Therapy in bipolar depression including type I and type II patients.
With so few treatments available for the management of bipolar depression, making TMS a non-drug treatment option could be groundbreaking,” said Dr. Scott Aaronson, Director of Clinical Research at Sheppard Pratt Health System and lead investigator of the study. “Results from this open label pilot study are quite promising and should lead to further efforts to make this treatment available to help as many patients as possible.
Clinical Outcomes of NeuroStar Advanced Therapy Treatment: The Largest Patient Registry for Depression Treatment with Transcranial Magnetic Stimulation—With more than 9,000 patients across more than 100 private practice locations in the U.S., Neuronetics’ Outcomes Registry is the largest registry documenting outcomes for any treatment of Major Depressive Disorder (MDD). This presentation will report new findings from the registry about the efficacy of NeuroStar Advanced Therapy in adult patients treated for an episode of MDD in community settings.
“Findings from Neuronetics’ Outcomes Registry document real-world outcomes, and further demonstrate that NeuroStar Advanced Therapy delivered in the community setting is an effective treatment for depression,” said Dr. Harold A. Sackeim, Professor of Clinical Psychology in Psychiatry and Radiology at the College of Physicians and Surgeons, Columbia University and lead author of the study. “Results from this large registry will help improve depression treatment protocols and treatment plans for individual patients.”
Leave a Reply